<i>BACE1</i> (rs638405) and <i>PRNP</i> codon 129 genotypic frequencies in control subjects and sCJD patients.

<p><i>BACE1</i> (rs638405) and <i>PRNP</i> codon 129 genotypic frequencies in control subjects and sCJD patients.</p

Demographic description and histogram of age distribution at clinical onset for sCJD (left) and sample procurement for controls (right) adjusted to normal distribution curves.

<p>Statistically significant differences between sCJD and control populations were observed for age (p<0.001) but not for gender distribution (p = 0.14).</p

Odds ratios for the association between sCJD and <i>BACE1</i> C-allele carriers at rs638405 among different strata defined by <i>PRNP</i> codon 129 genotypes.

<p>Odds ratios for the association between sCJD and <i>BACE1</i> C-allele carriers at rs638405 among different strata defined by <i>PRNP</i> codon 129 genotypes.</p

Synergy in sCJD population between <i>APOE</i> and <i>PRNP</i> genes.

a<p><i>APOE</i> ε4 allele: − = no copies of ε4 allele, + = one or two copies of ε4 allele;</p>b<p>OR calculated by a logistic regression model controlling by age as a linear variable and gender, and introducing the <i>PRNP</i>×<i>APOE</i> interaction factor as third independent variable.</p

Synergy in AD population between <i>APOE</i> and <i>PRNP</i> genes.

a<p><i>APOE</i> ε4 allele: − = no copies of ε4 allele, + = one or two copies of ε4 allele;</p>b<p>OR calculated by a logistic regression model controlling by age, linear values, and gender and using the <i>PRNP</i>×<i>APOE</i> interaction factor as third independent variable;</p>c<p>OR calculated by chi-square.</p

Odds ratios for the association between CJD and <i>PRNP</i> codon 129 in different strata defined by <i>APOE</i> ε4 allele status (M129V genotype is taken as reference or non-exposed).

a<p><i>APOE</i> ε4− = no copies of ε4 allele;</p>b<p><i>APOE</i> ε4+ = one or two copies of ε4 allele.</p

Odds ratios for the association between CJD and <i>APOE</i> ε4 carriers (vs. <i>APOE</i> ε4 non-carriers) among different strata defined by <i>PRNP</i> codon 129 genotypes.

<p>Odds ratios for the association between CJD and <i>APOE</i> ε4 carriers (vs. <i>APOE</i> ε4 non-carriers) among different strata defined by <i>PRNP</i> codon 129 genotypes.</p

<i>APOE</i> and <i>PRNP</i> codon 129 genotypic and allelic frequencies in control subjects (Cont) and patients (AD, sCJD).

a<p><i>APOE</i> ε4 status: ε4− = no copies of ε4 allele, ε4+ = one or two copies of ε4 allele.</p

Odds ratios for the association between Alzheimer's disease and <i>APOE</i> ε4 carriers (vs. <i>APOE</i> ε4 non-carriers) among different strata defined by <i>PRNP</i> codon 129 genotypes.

<p>Odds ratios for the association between Alzheimer's disease and <i>APOE</i> ε4 carriers (vs. <i>APOE</i> ε4 non-carriers) among different strata defined by <i>PRNP</i> codon 129 genotypes.</p

Presence of activated PKR in human brain tissue.

<p>The presence of activated PKR -autophosphorylated at Thr446- was studied in human brain sections (temporal lobe) from one non-demented control and one AD patient by immunohistochemistry (A). Colocalization of BACE1 and p-PKR(T446) in neurons from an AD patient. All brain sections analysed were positive for HSV1 infection as previously reported <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0021456#pone.0021456-Wozniak3" target="_blank">[39]</a> (B).</p